Dark Forest Capital Management LP Denali Therapeutics Inc. Transaction History

Dark Forest Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$11.47 - $16.65 $600,878 - $872,243	-52,387 Reduced 64.82%	28,433 $397,000
Q1 2025 May 15, 2025	BUY	$13.6 - $23.59 $923,875 - $1.6 Million	67,932 Added 527.09%	80,820 $1.1 Million
Q4 2024 Feb 14, 2025	BUY	$20.24 - $31.58 $260,853 - $407,003	12,888 New	12,888 $262,000
Q1 2022 May 13, 2022	SELL	$29.0 - $47.27 $15,341 - $25,005	-529 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$42.59 - $55.02 $2,810 - $3,631	-66 Reduced 11.09%	529 $24,000

Q3 2021 Nov 12, 2021	BUY	$48.48 - $78.23 $28,700 - $46,312	592 Added 19733.33%	595 $30,000
Q2 2021 Aug 16, 2021	BUY	$50.3 - $78.44 $150 - $235	3 New	3 $0

262

133M

219K

107K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.34B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Dark Forest Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Dark Forest Capital Management LP with notifications on news.